These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 18850301)
21. Systemic levels of CCL2, CCL3, CCL4 and CXCL8 differ according to age, time period and season among children newly diagnosed with type 1 diabetes and their healthy siblings. Thorsen SU; Eising S; Mortensen HB; Skogstrand K; Pociot F; Johannesen J; Svensson J; Scand J Immunol; 2014 Dec; 80(6):452-61. PubMed ID: 25201044 [TBL] [Abstract][Full Text] [Related]
22. Effective treatment of an elderly patient with Gaucher's disease and Parkinsonism: a case report of 24 months' oral substrate reduction therapy with miglustat. Hughes DA; Ginsberg L; Baker R; Goodwin S; Milligan A; Richfield L; Mehta AB Parkinsonism Relat Disord; 2007 Aug; 13(6):365-8. PubMed ID: 17049454 [TBL] [Abstract][Full Text] [Related]
23. Generation of osteoclasts from type 1 Gaucher patients and correlation with clinical and genetic features of disease. Reed MC; Bauernfreund Y; Cunningham N; Beaton B; Mehta AB; Hughes DA Gene; 2018 Dec; 678():196-206. PubMed ID: 30099023 [TBL] [Abstract][Full Text] [Related]
24. High-Dose Ambroxol Therapy in Type 1 Gaucher Disease Focusing on Patients with Poor Response to Enzyme Replacement Therapy or Substrate Reduction Therapy. Istaiti M; Frydman D; Dinur T; Szer J; Revel-Vilk S; Zimran A Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047707 [TBL] [Abstract][Full Text] [Related]
25. Bone complications in children with Gaucher disease. Bembi B; Ciana G; Mengel E; Terk MR; Martini C; Wenstrup RJ Br J Radiol; 2002; 75 Suppl 1():A37-44. PubMed ID: 12036831 [TBL] [Abstract][Full Text] [Related]
26. Biomarkers in Serbian patients with Gaucher disease. Sumarac Z; Suvajdžić N; Ignjatović S; Majkić-Singh N; Janić D; Petakov M; Dorđević M; Mitrović M; Dajak M; Golubović M; Rodić P Clin Biochem; 2011 Aug; 44(12):950-4. PubMed ID: 21640089 [TBL] [Abstract][Full Text] [Related]
27. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Charrow J; Dulisse B; Grabowski GA; Weinreb NJ Clin Genet; 2007 Mar; 71(3):205-11. PubMed ID: 17309642 [TBL] [Abstract][Full Text] [Related]
28. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase. Smith L; Rhead W; Charrow J; Shankar SP; Bavdekar A; Longo N; Mardach R; Harmatz P; Hangartner T; Lee HM; Crombez E; Pastores GM Mol Genet Metab; 2016 Feb; 117(2):164-71. PubMed ID: 26043810 [TBL] [Abstract][Full Text] [Related]
29. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Andersson H; Kaplan P; Kacena K; Yee J Pediatrics; 2008 Dec; 122(6):1182-90. PubMed ID: 19047232 [TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease. Elstein D; Mehta A; Hughes DA; Giraldo P; Charrow J; Smith L; Shankar SP; Hangartner TN; Kunes Y; Wang N; Crombez E; Zimran A Am J Hematol; 2015 Jul; 90(7):592-7. PubMed ID: 25776130 [TBL] [Abstract][Full Text] [Related]
31. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). Hughes DA; Deegan P; Giraldo P; Göker-Alpan Ö; Lau H; Lukina E; Revel-Vilk S; Scarpa M; Botha J; Gadir N; Zimran A; J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36079085 [TBL] [Abstract][Full Text] [Related]
32. [High dose of enzyme replacement therapy was successful for the pulmonary involvement in a case of type 2 Gaucher disease]. Arai N; Uematsu M; Abe Y; Fukuyo N; Wakusawa K; Kikuchi A; Sakamoto O; Ohura T; Tsuchiya S No To Hattatsu; 2010 Jan; 42(1):45-9. PubMed ID: 23858612 [TBL] [Abstract][Full Text] [Related]